

David Gillatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9375035/publications.pdf>

Version: 2024-02-01

33
papers

3,883
citations

516215

16
h-index

500791

28
g-index

34
all docs

34
docs citations

34
times ranked

5506
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq1 1 0.784314 rgBT /Overlo	1.3	23
2	Age-related urologic problems in the complex urologic patient. World Journal of Urology, 2021, 39, 1037-1044.	1.2	6
3	High-dose vitamin D supplementation to prevent prostate cancer progression in localised cases with low-to-intermediate risk of progression on active surveillance (ProsD): protocol of a phase II randomised controlled trial. BMJ Open, 2021, 11, e044055.	0.8	3
4	Safety and tolerability of Miltuximab - a first in human study in patients with advanced solid cancers. Asia Oceania Journal of Nuclear Medicine and Biology, 2021, 9, 86-100.	0.1	2
5	Rapid and Label-Free Isolation of Tumour Cells from the Urine of Patients with Localised Prostate Cancer Using Inertial Microfluidics. Cancers, 2020, 12, 81.	1.7	52
6	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. European Urology, 2020, 77, 320-330.	0.9	107
7	Strategies adopted by men to deal with uncertainty and anxiety when following an active surveillance/monitoring protocol for localised prostate cancer and implications for care: a longitudinal qualitative study embedded within the ProtecT trial. BMJ Open, 2020, 10, e036024.	0.8	7
8	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1731-1738.	1.1	27
9	Development and evaluation of the MiCheck test for aggressive prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 683.e11-683.e18.	0.8	3
10	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. Health Technology Assessment, 2020, 24, 1-176.	1.3	22
11	Appraising risk in active surveillance of localized prostate cancer. Health Expectations, 2019, 22, 1028-1039.	1.1	5
12	Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells. Biomolecules, 2019, 9, 820.	1.8	13
13	IGFBP-2 acts as a tumour suppressor and plays a role in determining chemosensitivity in bladder cancer cells. Oncotarget, 2019, 10, 7043-7057.	0.8	8
14	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. Journal of Clinical Epidemiology, 2018, 96, 35-46.	2.4	16
15	Is robotic radical cystectomy ready for prime time?. ANZ Journal of Surgery, 2018, 88, 948-949.	0.3	0
16	ProDiet: A Phase II Randomized Placebo-controlled Trial of Green Tea Catechins and Lycopene in Men at Increased Risk of Prostate Cancer. Cancer Prevention Research, 2018, 11, 687-696.	0.7	32
17	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. European Urology, 2017, 71, 381-388.	0.9	41
18	Communicating risk in active surveillance of localised prostate cancer: a protocol for a qualitative study. BMJ Open, 2017, 7, e017372.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Radiotherapy for Prostate Cancer: is it "what you do"™ or "the way that you do it"™? A UK Perspective on Technique and Quality Assurance. <i>Clinical Oncology</i> , 2016, 28, e92-e100.	0.6	7
20	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
21	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
22	Design of a multi-DOF cable-driven mechanism of a miniature serial manipulator for robot-assisted minimally invasive surgery. , 2016, , .		8
23	Prostate cancer - evidence of exercise and nutrition trial (PrEvENT): study protocol for a randomised controlled feasibility trial. <i>Trials</i> , 2016, 17, 123.	0.7	14
24	Salvage Radical Assisted Laparoscopic Prostatectomy After Low-Dose Rate Brachytherapy. <i>Videourology (New Rochelle, N Y)</i> , 2016, 30, .	0.1	0
25	Robot-assisted radical cystectomy with intracorporeal urinary diversion: impact on an established enhanced recovery protocol. <i>BJU International</i> , 2015, 116, 924-931.	1.3	53
26	Proteomics discovery of radioresistant cancer biomarkers for radiotherapy. <i>Cancer Letters</i> , 2015, 369, 289-297.	3.2	21
27	The status of surgery in the management of high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2014, 11, 342-351.	1.9	34
28	μAngelo: A novel minimally invasive surgical system based on an anthropomorphic design. , 2014, , .		4
29	Development of a complex intervention improved randomization and informed consent in a randomized controlled trial. <i>Journal of Clinical Epidemiology</i> , 2009, 62, 29-36.	2.4	133
30	Antiandrogen treatments in locally advanced prostate cancer: are they all the same?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 17-26.	1.2	46
31	Screen-detected prostate cancer and the insulin-like growth factor axis: Results of a population-based case-control study. <i>International Journal of Cancer</i> , 2004, 108, 887-892.	2.3	51
32	Expression of neuropilin-1 by human glomerular epithelial cells in vitro and in vivo. <i>Clinical Science</i> , 2001, 101, 439-446.	1.8	42
33	Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom. <i>BMJ: British Medical Journal</i> , 1999, 318, 299-300.	2.4	40